Sanofi's Pediatric Hexavalent Vaccine Approved by U.S. FDA

By Reuters Staff

December 27, 2018

PARIS (Reuters) - The U.S. Food and Drug Administration approved Sanofi's new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

The new vaccine, dubbed Vaxelis, is designed for to be used in children aged 6 weeks to 4 years old, to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type B.

Sanofi developed Vaxelis in partnership with Merck.

Sanofi and Merck are now working on the production and supply of Vaxelis aiming to make it available on the market in 2020 or later.